News

Did Eli Lilly Just Say Checkmate to Novo Nordisk?
Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world ...
Prediction: Eli Lilly's Newest GLP-1 Drug Will Be a Game-Changer for the Stock
Let's look at why this news could be a game-changer for Eli Lilly and its stock.
Why It Makes Sense To Buy Eli Lilly Stock At $840
The trial met its primary objectives, showing the pill’s effectiveness in helping patients with Type 2 diabetes achieve ...
The Score: UnitedHealth, Netflix, Eli Lilly and More Stocks That Defined the Week
Pharmaceutical companies—including Eli Lilly and Novo Nordisk, which currently dominate the obesity market—have been testing ...
Is Eli Lilly Stock a Buy Right Now?
Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly ( LLY 14.56%). But now, an investment ...
S&P 500 ends up as Eli Lilly jumps and UnitedHealth plummets
The S&P 500 ended higher on Thursday, lifted by Eli Lilly and Apple, as investors weighed progress in U.S. trade negotiations ...
Eli Lilly CEO Ricks Warns Against Unintentionally Raising Prices as Weight-Loss Pill Nears Market Launch
Eli Lilly is getting closer to bringing a weight loss pill to market, but CEO David Ricks notes certain factors need to be considered to prevent prices from ballooning.
Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron's Promising Phase 3 Results
Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...